Avonex Labeling Change Will Not Affect Sales, Accredo CFO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A warning on hepatic injury recently added to Biogen Idec's Avonex labeling "will have little, if any, impact on" sales, Accredo CFO Kimbrough says. The specialty pharmacy distributor handles 40% of U.S. Avonex sales.